Overview

Dose Escalation Trial of Stereotactic Body Radiation Therapy (SBRT) in Combination With GC4419 in Pancreatic Cancer

Status:
Active, not recruiting

Trial end date:
2022-06-01

Target enrollment:

Participant gender:

Summary

The purpose of the phase I/II clinical study is to determine the best dose of fractionated stereotactic radiation therapy (SBRT) given either with Avasopasem (GC4419) or placebo to patients who have been diagnosed with locally advanced pancreatic cancer.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Galera Therapeutics, Inc.

Collaborator:

M.D. Anderson Cancer Center

Treatments:

Avasopasem manganese